Psychedelics for Substance Use Disorders: Updates for the Psychiatric Trainee
Psychedelics have recently gained attention as potential therapeutic agents for treating patients with substance use disorders, with studies showing promise of psychedelics for reducing substance use and cravings. Despite a limited number of well-controlled modern trials examining psilocybin treatment for alcohol or tobacco use disorder, the available evidence suggests that many serotonergic psychedelics may have benefits for managing various substance use disorders. In this narrative review, the authors aimed to critically evaluate the literature on the use of psychedelics for substance use disorders, including evidence for their efficacy, safety, and potential risks.
Authors
- Lawrence Canale
- Jeremy Weleff (ORCID: https://orcid.org/0000-0001-8071-7412)
- Dhvanit Raval
- Preet Chatha
- Lauren Wilseck
Institutions
- Kansas City University (US)
- Welch Foundation (US)
- Air Force Medical University (CN)
Publication Details
- Journal
- American Journal of Psychiatry Residents Journal
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1176/appi.ajp-rj.2025.200301
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00